These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27899953)

  • 1. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.
    Pantziarka P; Bouche G; Sukhatme V; Meheus L; Rooman I; Sukhatme VP
    Ecancermedicalscience; 2016; 10():680. PubMed ID: 27899953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.
    Pantziarka P; Sukhatme V; Bouche G; Meheus L; Sukhatme VP
    Ecancermedicalscience; 2016; 10():610. PubMed ID: 26823679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.
    Pantziarka P; Sukhatme V; Bouche G; Meheus L; Sukhatme VP
    Ecancermedicalscience; 2015; 9():521. PubMed ID: 25932045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.
    Sukhatme V; Bouche G; Meheus L; Sukhatme VP; Pantziarka P
    Ecancermedicalscience; 2015; 9():568. PubMed ID: 26435741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.
    Pantziarka P; Bouche G; Meheus L; Sukhatme V; Sukhatme VP
    Ecancermedicalscience; 2014; 8():485. PubMed ID: 25525463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ReDO_DB: the repurposing drugs in oncology database.
    Pantziarka P; Verbaanderd C; Sukhatme V; Rica Capistrano I; Crispino S; Gyawali B; Rooman I; Van Nuffel AM; Meheus L; Sukhatme VP; Bouche G
    Ecancermedicalscience; 2018; 12():886. PubMed ID: 30679953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.
    Pantziarka P; Bouche G; Meheus L; Sukhatme V; Sukhatme VP
    Ecancermedicalscience; 2014; 8():443. PubMed ID: 25075217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.
    Pantziarka P; Sukhatme V; Crispino S; Bouche G; Meheus L; Sukhatme VP
    Ecancermedicalscience; 2018; 12():824. PubMed ID: 29743944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.
    Verbaanderd C; Maes H; Schaaf MB; Sukhatme VP; Pantziarka P; Sukhatme V; Agostinis P; Bouche G
    Ecancermedicalscience; 2017; 11():781. PubMed ID: 29225688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.
    Van Nuffel AM; Sukhatme V; Pantziarka P; Meheus L; Sukhatme VP; Bouche G
    Ecancermedicalscience; 2015; 9():513. PubMed ID: 25729426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propranolol and breast cancer-a work in progress.
    Pantziarka P; Bryan BA; Crispino S; Dickerson EB
    Ecancermedicalscience; 2018; 12():ed82. PubMed ID: 30034523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Repurposing Drugs in Oncology (ReDO) Project.
    Pantziarka P; Bouche G; Meheus L; Sukhatme V; Sukhatme VP; Vikas P
    Ecancermedicalscience; 2014; 8():442. PubMed ID: 25075216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.
    Montoya A; Amaya CN; Belmont A; Diab N; Trevino R; Villanueva G; Rains S; Sanchez LA; Badri N; Otoukesh S; Khammanivong A; Liss D; Baca ST; Aguilera RJ; Dickerson EB; Torabi A; Dwivedi AK; Abbas A; Chambers K; Bryan BA; Nahleh Z
    Oncotarget; 2017 Jan; 8(4):6446-6460. PubMed ID: 28031536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing of drugs for triple negative breast cancer: an overview.
    Spini A; Donnini S; Pantziarka P; Crispino S; Ziche M
    Ecancermedicalscience; 2020; 14():1071. PubMed ID: 32728387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha- and beta-receptor blocking drugs in the treatment of hypertension.
    Ram CV; Kaplan NM
    Curr Probl Cardiol; 1979 Jan; 3(10):1-53. PubMed ID: 40755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer.
    Montoya A; Varela-Ramirez A; Dickerson E; Pasquier E; Torabi A; Aguilera R; Nahleh Z; Bryan B
    Biomed J; 2019 Jun; 42(3):155-165. PubMed ID: 31466709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The β 2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and Metastasis of the Human Breast Cancer MDA-MB- 231 Cell Line.
    Rivero EM; Piñero CP; Gargiulo L; Entschladen F; Zänker K; Bruzzone A; Lüthy IA
    Curr Cancer Drug Targets; 2017; 17(8):756-766. PubMed ID: 28359245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression.
    Brohée L; Peulen O; Nusgens B; Castronovo V; Thiry M; Colige AC; Deroanne CF
    Sci Rep; 2018 May; 8(1):7050. PubMed ID: 29728578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs.
    Regulska K; Regulski M; Karolak B; Michalak M; Murias M; Stanisz B
    Pharmacol Res; 2019 Sep; 147():104326. PubMed ID: 31340189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action.
    Zanelatto FB; Dias EV; Teixeira JM; Sartori CR; Parada CA; Tambeli CH
    Eur J Pain; 2018 Mar; 22(3):572-582. PubMed ID: 29226500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.